Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 2, Issue 2, 2016, Pages 121-130

  Koppel, Jeremy ^a   Jimenez, Heidy ^a   Adrien, Leslie ^a   Greenwald, Blaine S ^b   Marambaud, Philippe ^a   Cinamon, Ezra ^c   Davies, Peter ^a  

^a Feinstein Institute of Medical Research   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c Rambam Mesivta High School   (United States)

Author keywords

Alzheimer's disease; AMPK; Antipsychotics; Dopamine; Haloperidol; Tau

Indexed keywords

AMYLOID BETA PROTEIN; HALOPERIDOL DECANOATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TOLERABILITY; HIPPOCAMPUS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 84978492590     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.05.003     Document Type: Article

References (73)

1. [1] Schneider, L.S., Dagerman, K., Insel, P.S., Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (2006), 191–210.
2. [2] Sultzer, D.L., Davis, S.M., Tariot, P.N., Dagerman, K.S., Lebowitz, B.D., Lyketsos, C.G., et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165 (2008), 844–854.
3. [3] Maher, A.R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.H., Ewing, B., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306 (2011), 1359–1369.
4. [4] Schneider, L.S., Dagerman, K.S., Insel, P., Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005), 1934–1943.
5. [5] FDA, Deaths with antipsychotics in elderly patients with behavioral disturbances. 2005, Public Health Advisory, Montgomery, Maryland.
6. [6] Vigen, C.L., Mack, W.J., Keefe, R.S., Sano, M., Sultzer, D.L., Stroup, T.S., et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 168 (2011), 831–839.
7. [7] Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16 (1995), 271–278 discussion 278-84.
8. [8] Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., Hyman, B.T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:3 Pt 1 (1992), 631–639.
9. [9] Braak, H., Braak, E., Neuropahological staging of Alzheimer-related changes. Acta Neuropath Appl Neurobiol 14 (1991), 39–44.
10. [10] Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol 12 (2013), 609–622.
11. [11] Seubert, P., Mawal-Dewan, M., Barbour, R., Jakes, R., Goedert, M., Johnson, G.V., et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem 270 (1995), 18917–18922.
12. [12] Augustinack, J.C., Schneider, A., Mandelkow, E.M., Hyman, B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103 (2002), 26–35.
13. [13] Ksiezak-Reding, H., Liu, W.K., Yen, S.H., Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res 597 (1992), 209–219.
14. [14] Goedert, M., Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16 (1993), 460–465.
15. [15] Iqbal, K., Wang, X., Blanchard, J., Liu, F., Gong, C.X., Grundke-Iqbal, I., Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans 38 (2010), 962–966.
16. [16] Medina, M., Avila, J., Further understanding of tau phosphorylation: implications for therapy. Expert Rev Neurother 15 (2015), 115–122.
17. [17] Chung, S.H., Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep 42 (2009), 467–474.
18. [18] Adams, C.E., Bergman, H., Irving, C.B., Lawrie, S., Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev, 2013, CD003082.
19. [19] Cipriani, A., Rendell, J.M., Geddes, J.R., Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev, 2006, CD004362.
20. [20] Lonergan, E., Britton, A.M., Luxenberg, J., Wyller, T., Antipsychotics for delirium. Cochrane Database Syst Rev, 2007, CD005594.
21. [21] Lonergan, E., Luxenberg, J., Colford, J., Haloperidol for agitation in dementia. Cochrane Database Syst Rev, 2002, CD002852.
22. [22] Schotte, A., Janssen, P.F., Megens, A.A., Leysen, J.E., Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631 (1993), 191–202.
23. [23] Kales, H.C., Kim, H.M., Zivin, K., Valenstein, M., Seyfried, L.S., Chiang, C., et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169 (2012), 71–79.
24. [24] Maust, D.T., Kim, H.M., Seyfried, L.S., Chiang, C., Kavanagh, J., Schneider, L.S., et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 72 (2015), 438–445.
25. [25] Nasrallah, H.A., Does the neurotoxicity of haloperidol explain the higher mortality in dementia patients compared with the second generation agents?. Am J Psychiatry 169 (2012), 663–664 author reply 664–5.
26. [26] Benitez-King, G., Ortiz-Lopez, L., Jimenez-Rubio, G., Ramirez-Rodriguez, G., Haloperidol causes cytoskeletal collapse in N1E-115 cells through tau hyperphosphorylation induced by oxidative stress: Implications for neurodevelopment. Eur J Pharmacol 644 (2010), 24–31.
27. [27] Casanova, M.F., Carosella, N.W., Gold, J.M., Kleinman, J.E., Weinberger, D.R., Powers, R.E., A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia. Psychiatry Res 49 (1993), 41–62.
28. [28] Powchik, P., Davidson, M., Nemeroff, C.B., Haroutunian, V., Purohit, D., Losonczy, M., et al. Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry 150 (1993), 1726–1727.
29. [29] Purohit, D.P., Davidson, M., Perl, D.P., Powchik, P., Haroutunian, V.H., Bierer, L.M., et al. Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry 33 (1993), 255–260.
30. [30] Arnold, S.E., Franz, B.R., Trojanowski, J.Q., Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiol Aging 15 (1994), 299–303.
31. [31] Arnold, S.E., Gur, R.E., Shapiro, R.M., Fisher, K.R., Moberg, P.J., Gibney, M.R., et al. Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. Am J Psychiatry 152 (1995), 731–737.
32. [32] Arnold, S.E., Trojanowski, J.Q., Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Schizophr Bull 22 (1996), 5–9.
33. [33] Higaki, J., Murphy, G.M. Jr., Cordell, B., Inhibition of beta-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. J Neurochem 68 (1997), 333–336.
34. [34] Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25 (2005), 10637–10647.
35. [35] Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005), 476–481.
36. [36] Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56 (1999), 241–247.
37. [37] Meyer, J.M., Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr 18 Suppl 1 (2013), 58–67 quiz 68.
38. [38] Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X., Korhonen, P., A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168 (2011), 603–609.
39. [39] Spanarello, S., La Ferla, T., The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol 9 (2014), 310–317.
40. [40] El-Mallakh, R.S., Decker, S., Morris, M., Li, X.P., Huff, M.O., El-Masri, M.A., et al. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006), 1261–1264.
41. [41] Barth, V.N., Chernet, E., Martin, L.J., Need, A.B., Rash, K.S., Morin, M., et al. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 78 (2006), 3007–3012.
42. [42] Girgenti, M.J., Nisenbaum, L.K., Bymaster, F., Terwilliger, R., Duman, R.S., Newton, S.S., Antipsychotic-induced gene regulation in multiple brain regions. J Neurochem 113 (2010), 175–187.
43. [43] Acker, C.M., Forest, S.K., Zinkowski, R., Davies, P., d'Abramo, C., Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging 34 (2013), 338–350.
44. [44] Mondragon-Rodriguez, S., Perry, G., Luna-Munoz, J., Acevedo-Aquino, M., Williams, S., Phosphorylation of tau protein at sites Ser is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol Appl Neurobiol 40 (2014), 121–135.
45. [45] Janocko, N.J., Brodersen, K.A., Soto-Ortolaza, A.I., Ross, O.A., Liesinger, A.M., Duara, R., et al. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 124 (2012), 681–692.
46. [46] Bozzi, Y., Borrelli, E., Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci 29 (2006), 167–174.
47. [47] Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M., Gogos, J.A., Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36 (2004), 131–137.
48. [48] Kraemer, B.C., Zhang, B., Leverenz, J.B., Thomas, J.H., Trojanowski, J.Q., Schellenberg, G.D., Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100 (2003), 9980–9985.
49. [49] McCormick, A.V., Wheeler, J.M., Guthrie, C.R., Liachko, N.F., Kraemer, B.C., Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry 73 (2013), 464–471.
50. [50] Medina, M., Avila, J., Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes. Expert Rev Neurother 13 (2013), 495–503.
51. [51] Cohen, P., Frame, S., The renaissance of GSK3. Nat Rev Mol Cell Biol 2 (2001), 769–776.
52. [52] Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102 (2005), 6990–6995.
53. [53] Caccamo, A., Oddo, S., Tran, L.X., LaFerla, F.M., Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170 (2007), 1669–1675.
54. [54] Sudduth, T.L., Wilson, J.G., Everhart, A., Colton, C.A., Wilcock, D.M., Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One, 7, 2012, e31993.
55. [55] Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., Hemmings, B.A., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995), 785–789.
56. [56] Kozlovsky, N., Amar, S., Belmaker, R.H., Agam, G., Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 9 (2006), 337–342.
57. [57] Kim, S.F., Huang, A.S., Snowman, A.M., Teuscher, C., Snyder, S.H., From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104 (2007), 3456–3459.
58. [58] Hardie, D.G., AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8 (2007), 774–785.
59. [59] Tek, C., Kucukgoncu, S., Guloksuz, S., Woods, S.W., Srihari, V.H., Annamalai, A., Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 10 (2016), 193–202.
60. [60] Muller, D.J., Kennedy, J.L., Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7 (2006), 863–887.
61. [61] Souza, R.P., Tiwari, A.K., Chowdhury, N.I., Ceddia, R.B., Lieberman, J.A., Meltzer, H.Y., et al. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J Psychiatr Res 46 (2012), 462–468.
62. [62] Choi, Y., Jeong, H.J., Liu, Q.F., Oh, S.T., Koo, B.S., Kim, Y., et al. Clozapine Improves Memory Impairment and Reduces Abeta Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. Mol Neurobiol, 2016.
63. [63] Vingtdeux, V., Davies, P., Dickson, D.W., Marambaud, P., AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol 121 (2011), 337–349.
64. [64] Takashima, A., Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in adult brain. J Pharmacol Sci 109 (2009), 174–178.
65. [65] Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83 (1986), 4913–4917.
66. [66] Iqbal, K., Zaidi, T., Bancher, C., Grundke-Iqbal, I., Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett 349 (1994), 104–108.
67. [67] Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., Mandelkow, E.M., Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38 (1999), 3549–3558.
68. [68] Barini, E., Antico, O., Zhao, Y., Asta, F., Tucci, V., Catelani, T., et al. Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Mol Neurodegener, 11, 2016, 16.
69. [69] Murray, P.S., Kumar, S., Demichele-Sweet, M.A., Sweet, R.A., Psychosis in Alzheimer's disease. Biol Psychiatry 75 (2014), 542–552.
70. [70] Koppel, J., Greenwald, B.S., Optimal treatment of Alzheimer's disease psychosis: challenges and solutions. Neuropsychiatr Dis Treat 10 (2014), 2253–2262.
71. [71] Steinberg, G.R., Kemp, B.E., AMPK in Health and Disease. Physiol Rev 89 (2009), 1025–1078.
72. [72] Nakamura, Y., Okuno, S., Kitani, T., Otake, K., Sato, F., Fujisawa, H., Immunohistochemical localization of Ca(2+)/calmodulin-dependent protein kinase kinase beta in the rat central nervous system. Neurosci Res 39 (2001), 175–188.
73. [73] Salminen, A., Kaarniranta, K., Haapasalo, A., Soininen, H., Hiltunen, M., AMP-activated protein kinase: a potential player in Alzheimer's disease. J Neurochem 118 (2011), 460–474.